Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VDC2008 + Cryotherapy in Advanced Prostate Cancer
NCT00753220Phase 2Terminated
- Sponsor
- Bostwick Laboratories, Inc.
- Start
- Aug 2009
- Primary completion
- May 2011
- Modality
- Prophylactic Vaccines, Cell Therapies, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of VDC-2008 in prostate cancer (PCa), sponsored by Bostwick Laboratories, Inc. Primary endpoint: Maximum Tolerated Dose at 1 year. Started Aug 2009; status: terminated.
02
Drugs
VDC-2008
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00753220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00753220.